|
1
|
Sartor O, Coleman R, Nilsson S, Heinrich
D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue
J, et al: Effect of radium-223 dichloride on symptomatic skeletal
events in patients with castration-resistant prostate cancer and
bone metastases: Results from a phase 3, double-blind, randomised
trial. Lancet Oncol. 15:738–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
European Medicines Agency: Zytiga
(abiraterone acetate) Summary of product characteristics.
https://www.ema.europa.eu/en/medicines/human/EPAR/zytigaSeptember
23–2011
|
|
3
|
Parker C, Nilsson S, Heinrich D, Helle SI,
O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, et
al: Alpha emitter radium-223 and survival in metastatic prostate
cancer. N Engl J Med. 369:213–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rosino-Sánchez A: Preventive management of
bone disease in advanced prostate cancer. Arch Esp Urol.
71:258–266. 2018.(In Spanish). PubMed/NCBI
|
|
5
|
Smith MR: Osteoporosis and other adverse
body composition changes during androgen deprivation therapy for
prostate cancer. Cancer Metastasis Rev. 21:159–166. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Smith MR: Diagnosis and management of
treatment-related osteoporosis in men with prostate carcinoma.
Cancer. 97:789–795. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tanvetyanon T: Physician practices of bone
density testing and drug prescribing to prevent or treat
osteoporosis during androgen deprivation therapy. Cancer.
103:237–241. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Diamond TH, Higano CS, Smith MR, Guise TA
and Singer FR: Osteoporosis in men with prostate carcinoma
receiving androgen-deprivation therapy: Recommendations for
diagnosis and therapies. Cancer. 100:892–899. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Coleman RE and McCloskey EV:
Bisphosphonates in oncology. Bone. 49:71–76. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cha TL, Wu TT, Vogelzang NJ, Huang CY,
Huang SP, Lin CC, Ou YC, Pang ST, Shen DH, Wu WJ and Chang WY:
Optimal usage of radium-223 in metastatic castration-resistant
prostate cancer. J Formos Med Assoc. 116:825–836. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Macherey S, Monsef I, Jahn F, Jordan K,
Yuen KK, Heidenreich A and Skoetz N: Bisphosphonates for advanced
prostate cancer. Cochrane Database Syst Rev.
12:CD0062502017.PubMed/NCBI
|
|
12
|
Poon Y, Pechlivanoglou P, Alibhai SMH,
Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME and Krahn M:
Systematic review and network meta-analysis on the relative
efficacy of osteoporotic medications: Men with prostate cancer on
continuous androgen-deprivation therapy to reduce risk of fragility
fractures. BJU Int. 121:17–28. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yap KKL, Wong W, Ji L, Groshen SG, Quinn
DI, Pinski JK, Bryce AH and Dorff TB: Impact of timing of
administration of bone supportive therapy on pain palliation from
radium-223. J Clin Oncol. 35 (Suppl 15):S50232017. View Article : Google Scholar
|
|
14
|
Saad F, Carles J, Gillessen S, Heidenreich
A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O,
et al: Radium-223 and concomitant therapies in patients with
metastatic castration-resistant prostate cancer: An international,
early access, open-label, single-arm phase 3b trial. Lancet Oncol.
17:1306–1316. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Saad F, Sternberg CN, Mulders PFA, Niepel
D and Tombal BF: The role of bisphosphonates or denosumab in light
of the availability of new therapies for prostate cancer. Cancer
Treat Rev. 68:25–37. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Heidenreich A, Bastian PJ, Bellmunt J,
Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T,
Zattoni F, et al: EAU guidelines on prostate cancer. Part II:
Treatment of advanced, relapsing, and castration-resistant prostate
cancer. Eur Urol. 65:467–479. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Saylor PJ: Bone targeted therapies for the
prevention of skeletal morbidity in men with prostate cancer. Asian
J Androl. 16:341–347. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Morgans AK and Smith MR: Bone-targeted
agents: Preventing skeletal complications in prostate cancer. Uro
Clin North Am. 39:533–546. 2012. View Article : Google Scholar
|
|
19
|
Bilezikian JP: Osteoporosis in men. J Clin
Endocrinol Metab. 84:3431–3434. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Udovicich C, Perera M, Hofman MS, Siva S,
Del Rio A, Murphy DG and Lawrentschuk N:
68Ga-prostate-specific membrane antigen-positron
emission tomography/computed tomography in advanced prostate
cancer: Current state and future trends. Prostate Int. 5:125–129.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
von Eyben FE, Picchio M, von Eyben R, Rhee
H and Bauman G: 68Ga-labeled prostate-specific membrane
antigen ligand positron emission tomography/computed tomography for
prostate cancer: A systematic review and meta-analysis. Eur Urol
Focus. 4:686–693. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Osman OM, Fahmy YR, El-Oraby AM, El-Basmy
AA and Amin YE: Role of diffusion WIs and T2 * GRE pulse sequences
in dubious vertebral marrow pathological lesions. J Egypt Natl Canc
Inst. 19:254–262. 2007.PubMed/NCBI
|
|
23
|
Cicala D, Briganti F, Casale L, Rossi C,
Cagini L, Cesarano E, Brunese L and Giganti M: Atraumatic vertebral
compression fractures: Differential diagnosis between benign
osteoporotic and malignant fractures by MRI. Musculoskelet Surg. 97
(Suppl 2):S169–S179. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brodowicz T, Hadji P, Niepel D and Diel I:
Early identification and intervention matters: A comprehensive
review of current evidence and recommendations for the monitoring
of bone health in patients with cancer. Cancer Treat Rev. 61:23–34.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sartor O, Coleman RE, Nilsson S, Heinrich
D, Helle SI, O'Sullivan JM, Vogelzang NJ, Bruland Ø, Kobina S,
Wilhelm S, et al: An exploratory analysis of alkaline phosphatase,
lactate dehydrogenase, and prostate-specific antigen dynamics in
the phase 3 ALSYMPCA trial with radium-223. Ann Oncol.
28:1090–1097. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nguyen NC, Shah M, Appleman LJ, Parikh R
and Mountz JM: Radium-223 therapy for patients with metastatic
castrate-resistant prostate cancer: An update on literature with
case presentation. Int J Mol Imaging. 2016:25680312016. View Article : Google Scholar : PubMed/NCBI
|
